Suto K, Takei N, Yokoyama K, Chiba M, Ishio T, Maeda M, Goto H, Endo T, Teshima T, Yang Y, Nakagawa M. Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma. Leukemia. 2025 Jan;39(1):243-247. doi: 10.1038/s41375-024-02441-1. Epub 2024 Oct 21. PMID: 39433928
Yokomaku Y, Teruya K, Watanabe D, Endo T, Minami R, Taguchi N, Cassidy T, Marongiu A, Thorpe D, Shirasaka T, Oka S. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment- experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort. PLoS One. 2025 Jan 8;20(1):e0313338. doi: 10.1371/journal.pone.0313338. eCollection 2025. PMID: 39774438
Shimada K, Yamaguchi M, Kuwatsuka Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto A, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Meguro A, Kin Y, Minami Y, Hashimoto D, Nishiyama T, Shimada S, Masaki Y, Okamoto M, Atsuta Y, Kiyoi H, Suzuki R, Nakamura S, Kinoshita T. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high- dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial. EClinicalMedicine. 2025 Jan 31;80:103078. doi: 10.1016/j.eclinm.2025.103078. eCollection 2025 Feb. PMID: 39968389
Miyashita N, Ohashi K, Onozawa M. Effectiveness and Safety of Home-Based RBC Transfusions in Advanced Hematologic and Solid Tumors. J Pain Symptom Manage. 2026 Jan;71(1):110-118.e1. doi: 10.1016/j.jpainsymman.2025.09.021. Epub 2025 Sep 23. PMID: 40998223
Goto H, Kumode T, Mishima Y, Kataoka K, Ogawa Y, Kanemura N, Shimada K, Uchida T, Kuroe Y, Kawasaki A, Sato J, Teshima T. Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1. Int J Clin Oncol. 2025 Feb;30(2):389-396. doi: 10.1007/s10147-024-02662-5. Epub 2024 Dec 9. PMID: 39652156
Munakata W, Kumode T, Goto H, Fukuhara N, Shimoyama T, Takeuchi M, Kawakita T, Kubo K, Sawa M, Uchida T, Mishima Y, Ichii M, Hanaya M, Matsumoto A, Kuriki M, Seike T, Izutsu K, Ishizawa K. A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study. Br J Haematol. 2025 Feb;206(2):541-550. doi: 10.1111/bjh.19994. Epub 2025 Jan 8. PMID: 39778876
Toyosaki M, Machida S, Tomizawa D, Okada M, Sawa M, Ueda Y, Omi A, Koroki Y, Teshima T. Temporal changes in corticosteroid dose during ibrutinib treatment in patients with cGVHD and pulmonary involvement. Int J Hematol. 2025 Mar;121(3):388-396. doi: 10.1007/s12185-024-03882-1. Epub 2024 Dec 10. PMID: 39653871
Miyashita N, Onozawa M, Kasahara K, Matsukawa T, Onodera Y, Suzuki K, Takaku T, Teshima T, Kondo T. CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5-BLTR Signaling Pathway. Cancer Sci. 2025 Apr;116(4):1115-1125. doi: 10.1111/cas.70007. Epub 2025 Feb 4. PMID: 39905783
Goto H, Sawa M, Fujiwara SI, Ri M, Ishida T, Takeuchi M, Ishitsuka K, Toyosaki M, Sunami K, Tsukada J, Sonoki T, Shimogomi A, Ichihashi Y, Ouchi Y, Miyamoto T, Hino M, Maeda Y, Teshima T. Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma. Sci Rep. 2025 Apr 25;15(1):14523. doi: 10.1038/s41598-025-98453-7. PMID: 40281003
Nguyen T, Tamai M, Fujisawa S, Nagamachi A, Kagami K, Komatsu C, Iwamoto S, Inaba T, Teshima T, Inukai T. Utility of the Base Editing System for Introducing Drug-Resistant Gene Mutations Into Human Leukemia Cellular Models. Cureus. 2025 Apr 8;17(4):e81889. doi: 10.7759/cureus.81889. eCollection 2025 Apr. PMID: 40342439
Arai Y, Brazauskas R, He N, Al-Homsi AS, Chhabra S, Battiwalla M, Yanada M, Steinberg A, Diaz Perez MA, Hong S, Kanda J, Bashey A, Frangoul HA, Badawy SM, Verdonck LF, Lazarus HM, Yared JA, Hashem H, Sharma A, Aljurf M, Dias AL, Abid MB, Wirk B, Freytes CO, Zeidan AM, Gergis U, Beitinjaneh A, Askar M, Pu JJ, Lehmann LE, Rangarajan HG, Wood WA, Hashmi S, Yano S, Kako S, Ozawa Y, Doki N, Kanda Y, Fukuda T, Katayama Y, Ichinohe T, Tanaka J, Teshima T, Okamoto S, Atsuta Y, Saber W. Efficacy of Total-Body Irradiation-based Intensified Myeloablative Regimens for Acute Leukemia-An International Collaborative Study. EJHaem. 2025 May 28;6(3):e70061. doi: 10.1002/jha2.70061. eCollection 2025 Jun. PMID: 40438703
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Oshima MU, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly LS, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Mendizabal A, Devine SM, Horowitz MM, Chen YB. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3- ITD-mutated AML. Blood. 2025 May 8;145(19):2138-2148. doi: 10.1182/blood.2024025154. PMID: 39775763
Kurosawa S, Fukuda T, Ichinohe T, Hashii Y, Kanda J, Goto H, Kato K, Ishimaru F, Yoshimitsu M, Hino M, Matsuo K, Ito Y, Yanagisawa A, Ohbiki M, Tabuchi K, Atsuta Y, Arai Y; Japanese Society for Transplantation and Cellular Therapy (JSTCT). Center effect on outcomes of second allogeneic hematopoietic stem cell transplantation for B-cell acute lymphoblastic leukemia: a nationwide retrospective study. Cytotherapy. 2025 Jun;27(6):733-743. doi: 10.1016/j.jcyt.2025.03.002. Epub 2025 Mar 12. PMID: 40156598
Kato M, Nakashone H, Matsuo K, Ito Y, Yanagisawa A, Ohbiki M, Tabuchi K, Ichinohe T, Hashii Y, Kanda J, Goto H, Kato K, Yoshimitsu M, Sato A, Hino M, Matsumoto K, Yakushijin K, Atsuta Y, Fukuda T. Impact of center volume on outcomes in allogeneic hematopoietic cell transplantation for children. Bone Marrow Transplant. 2025 Jun;60(6):851-856. doi: 10.1038/s41409-025-02569-3. Epub 2025 Apr 10. PMID: 40211066
Goto T, Okamura H, Ikeda T, Mori Y, Shiratori S, Fujiwara SI, Doki N, Matsuoka KI, Katayama Y, Chen YB, Fløisand Y, Rossiter G, Jansson J, Nakaya R, Teshima T. Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study. Int J Hematol. 2025 Jul;122(1):93-105. doi: 10.1007/s12185-025-03955-9. Epub 2025 Mar 12. PMID: 40072824
Nakamura N, Morishita T, Hayashi H, Okabe M, Nakasone H, Uchida N, Doki N, Fukuda T, Yoshihara S, Tanaka M, Nishida T, Hasegawa Y, Matsuoka KI, Sawa M, Eto T, Onizuka M, Katayama Y, Kato K, Ishimaru F, Tabuchi K, Atsuta Y, Kanemura N, Teshima T. The impact of the SARS-CoV-2 pandemic on umbilical cord blood transplantation in Japan: insights from an interrupted time series analysis. Bone Marrow Transplant. 2025 Jul;60(7):964-970. doi: 10.1038/s41409-025-02588-0. Epub 2025 Apr 17. PMID: 40240501
Ito Y, Shimono J, Kawamoto K, Hatanaka KC, Kogure Y, Tabata M, Saito Y, Mizuno K, Horie S, Mizukami Y, Koya J, Murakami K, Teshima T, Hatanaka Y, Chiba K, Okada A, Shiraishi Y, Miyoshi H, Matsuno Y, Ohshima K, Kataoka K, Nakagawa M. TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma. Leukemia. 2025 Jul;39(7):1723-1734. doi: 10.1038/s41375-025-02631-5. Epub 2025 May 2. PMID: 4031669
Shiratori S, Sugita J, Ishikawa J, Kuroha T, Mori Y, Eto T, Kasahara S, Fukushima K, Harada M, Teshima T. A comparative study of GVHD prophylaxis using low dose ATG versus PTCy for PBSCT based on two independent prospective cohorts. Sci Rep. 2025 Jul 1;15(1):20677. doi: 10.1038/s41598-025-07263-4. PMID: 40596499
Kanaya M, Onozawa M, Matsukawa T, Miyashita N, Fujii F, Yoshida S, Nagai J, Aiba M, Hidaka D, Hashiguchi J, Senjo H, Igarashi T, Chiba M, Yamamoto S, Shimizu T, Ishio T, Yokoyama S, Ebata K, Iyama S, Oyake T, Kondo T, Teshima T. Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine- venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net. Blood Cancer J. 2025 Jul 3;15(1):118. doi: 10.1038/s41408-025-01324-7. PMID: 40610408
Ito Y, Shimono J, Kawamoto K, Hatanaka KC, Kogure Y, Tabata M, Saito Y, Mizuno K, Horie S, Mizukami Y, Koya J, Murakami K, Teshima T, Hatanaka Y, Chiba K, Okada A, Shiraishi Y, Miyoshi H, Matsuno Y, Ohshima K, Kataoka K, Nakagawa M. TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma. Leukemia. 2025 Jul;39(7):1723-1734. doi: 10.1038/s41375-025-02631-5. Epub 2025 May 2. PMID: 40316697
Makishima H, Mikasa T, Isogaya K, Miyamoto T, Yamauchi T, Yokota A, Onozawa M, Ando K, Ogawa Y, Usuki K, Yamauchi T, Ota S, Takada S, Morita Y, Ishikawa T, Takenaka K, Kuroda J, Sekiguchi N, Kawakita T, Miyazaki Y. Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351. Int J Hematol. 2025 Jul;122(1):57-65. doi: 10.1007/s12185-025-03956-8. Epub 2025 Feb 27. PMID: 40016445
Trněný M, Fogliatto L, Gardner F, Flinn I, Larouche JF, Haioun C, Canales M, Goto H, Hajek R, Salles G, Singh A, Yan M, Kothari R, Man G, Sahin D, Hirata J, Lee C, Tilly H, Flowers CR. Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes. Blood Adv. 2025 Jul 8;9(13):3263-3267. doi: 10.1182/bloodadvances.2024014695. PMID: 40088467
Iwasaki M, Kanda J, Tanaka H, Ikegame K, Shindo T, Kawase T, Yoshihara S, Doki N, Nakamae H, Eto T, Tanaka T, Ara T, Hiramoto N, Kondo Y, Matsuoka KI, Ando T, Shono K, Nagafuji K, Fukuda T, Ichinohe T, Atsuta Y, Murata M, Morishima S. Impact of HLA Epitope Matching on Outcomes in Haploidentical HSCT With Distinct GVHD Prophylaxes. Transplantation. 2025 Jul 1;109(7):1241-1250. doi: 10.1097/TP.0000000000005347. Epub 2025 Feb 14. PMID: 39948727
Akahoshi Y, Nakasone H, Takenaka K, Ara T, Tada Y, Doki N, Uchida N, Tanaka M, Hasegawa Y, Takeda W, Nishida T, Ishikawa J, Kurita N, Sawa M, Onizuka M, Kako S, Fujiwara SI, Kataoka K, Kawamura K, Fukuda T, Atsuta Y, Yakushijin K, Kanda Y. Heterogeneity of Survival Benefit Conferred By Letermovir. Transplant Cell Ther. 2025 Jul;31(7):461.e1-461.e12. doi: 10.1016/j.jtct.2025.04.010. Epub 2025 Apr 28. PMID: 40306552
Matsukawa T, Sugita J, Hashimoto D, Aiba M, Okada K, Teshima T. Early cardiotoxicity in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after HLA-haploidentical hematopoietic stem cell transplantation. Int J Hematol. 2025 Aug;122(2):247-256. doi: 10.1007/s12185-025-03970-w. Epub 2025 Mar 23. PMID: 40121595
Zeiser R, Russo D, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hamad N, Burock K, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F. Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft- Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study. J Clin Oncol. 2025 Aug 10;43(23):2566-2571. doi: 10.1200/JCO-24-02477. Epub 2025 Jun 25. PMID: 40561385
Kanao-Kanda M, Luthe SK, Onodera Y, Sato I, Endo T, Kawamata T, Kanda H. Prevalence of HIV-related pain in Japan: a clinical survey. J Anesth. 2025 Aug;39(4):530-544. doi: 10.1007/s00540-025-03493-y. Epub 2025 Apr 16. PMID: 40237886
Kato K, Kato J, Goto H, Kobayashi T, Takahashi Y, Sakaida E, Hiramatsu H, Yamamoto M, Yoshihara S, Ando J, Koh K, Fukushima K, Iwamoto F, Tiwari R, Fujii N. Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trial. Cytotherapy. 2025 Aug;27(8):938-943. doi: 10.1016/j.jcyt.2025.04.067. Epub 2025 Apr 18. PMID: 40377509
Nishida M, Hirabayashi S, Iwai T, Sato M, Kudo Y, Omotehara S, Horie T, Sakano R, Terashita Y, Cho Y, Manabe A, Teshima T. Ultrasonographic scoring system for SOS/VOD in pediatric hematopoietic stem cell transplant recipients. Int J Hematol. 2025 Sep;122(3):434-443. doi: 10.1007/s12185-025-03995-1. Epub 2025 Apr 26. PMID: 40285798
Yoshida S, Onozawa M, Yokoyama S, Matsukawa T, Goto H, Hirabayashi S, Kondo T, Hashimoto D, Onodera Y, Teshima T. Peposertib suppresses generation of FLT3-internal tandem duplication formed by contralateral double nicks. Exp Hematol. 2025 Sep;149:104819. doi: 10.1016/j.exphem.2025.104819. Epub 2025 May 31. PMID: 40456437
Akahoshi Y, Inamoto Y, Spyrou N, Nakasone H, Diniz M, Asada N, Ayuk FA, Choe HK, Doki N, Eto T, Etra AM, Hexner EO, Hiramoto N, Hogan WJ, Holler E Prof Dr med, Kataoka K, Kawakita T, Tanaka M, Tanaka T, Uchida N, Vasova I, Yoshihara S, Ishimaru F, Fukuda T, Chen YB, Kanda J, Nakamura R, Atsuta Y, Ferrara JLM, Kanda Y, Levine JE, Teshima T. Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC. Blood Adv. 2025 Sep 23;9(18):4640-4653. doi: 10.1182/bloodadvances.2025016233. PMID: 40590886
Mishima Y, Hashimoto D, Ichii M, Fukuhara N, Uchida T, Kato K, Omi A, Koroki Y, Shiga K, Maruyama D. Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE. Ann Hematol. 2025 Sep;104(9):4605-4610. doi: 10.1007/s00277-025-06569-7. Epub 2025 Sep 13. PMID: 40940567
Ichikawa T, Tamura T, Nao N, Suzuki H, Maruyama S, Wada D, Tsujino S, Yoshinaga N, Asagoe K, Takahata M, Ishio T, Ibata M, Yoko T, Kakinoki Y, Okubo K, Suzuki R, Suzuki S, Nakamori Y, Teshima T, Fukuhara T. Characterization of remdesivir resistance mutations in COVID-19 patients with various immunosuppressive diseases. Antiviral Res. 2025 Oct;242:106264. doi: 10.1016/j.antiviral.2025.106264. Epub 2025 Aug 28. PMID: 40885288
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Oshima MU, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly LS, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson K, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal A, Devine SM, Horowitz MM, Chen YB. Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia. Blood Adv. 2025 Oct 28;9(20):5123-5133. doi: 10.1182/bloodadvances.2025016306. PMID: 40590852
Shimomura Y, Terakura S, Matsuo K, Ito Y, Ichinohe T, Hashii Y, Goto H, Kato K, Kawamura K, Onizuka M, Ishimaru F, Takahashi Y, Yanagisawa A, Ohbiki M, Tabuchi K, Atsuta Y, Fukuda T, Kanda J, Murata M. Impact of center volume on acute graft versus host disease in allogeneic stem cell transplant recipients. Int J Hematol. 2025 Oct;122(4):559-571. doi: 10.1007/s12185-025-04003-2. Epub 2025 May 20. PMID: 40392463
Tamai M, Komatsu C, Kagami K, Kasai S, Watanabe A, Akahane K, Goi K, Tomoyasu C, Imamura T, Oguri S, Iwasaki S, Teshima T, Yatabe Y, Inukai T. A characteristic gene expression profile regulated by ACIN1::NUTM1 fusion in a newly identified infant leukaemic cell line and an ACIN1::NUTM1-inducible model. Br J Haematol. 2025 Nov;207(5):1842-1854. doi: 10.1111/bjh.70130. Epub 2025 Aug 29. PMID: 40884014
Shiratori S, Suto K, Hasegawa Y, Ara T, Matsukawa T, Goto H, Onozawa M, Nakagawa M, Kahata K, Hidaka D, Ogasawara R, Okada K, Sugita J, Kakinoki Y, Ota S, Hashimoto D, Teshima T. Safety and Efficacy of Graft-versus-Host Disease Prophylaxis with Mini-Dose Methotrexate in Umbilical Cord Blood Transplantation: An NJHSG-CBT18 Observational Study. Transplant Cell Ther. 2025 Nov 6:S2666-6367(25)01549-0. doi: 10.1016/j.jtct.2025.10.035. Online ahead of print. PMID: 41205871
Takahashi N, Kikushige Y, Nakamae H, Goto T, Tomita A, Ichii M, Ito S, Teshima T, Kirito K, Ikezoe T, Hatano K, Tanaka H, Hiramoto N, Osako R, Aoki M, Malek K, Ueda Y. Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST. Int J Hematol. 2025 Nov;122(5):647-659. doi: 10.1007/s12185-025-04014-z. Epub 2025 May 26. PMID: 40418277
Nakano K, Seimiya M, Kojima K, Yamashita N, Goto H, Teshima T. Effect of eltrombopag on biochemical assay parameters. J Pharm Biomed Anal. 2025 Nov 15;265:117015. doi: 10.1016/j.jpba.2025.117015. Epub 2025 Jun 6. PMID: 40513306
Maziarz RT, Bishop MR, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu J, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Ma W, Han X, Nuortti M, Awasthi R, Mundt KE, Majdan M, Maier HJ, Jegerlehner A, Salles G, Schuster SJ. Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma. J Clin Oncol. 2025 Nov 18:JCO2500507. doi: 10.1200/JCO-25-00507. Online ahead of print. PMID: 41252666
Kato K, Inamoto Y, Kawakita T, Onishi Y, Matsuoka KI, Shiratori S, Ikegame K, Hiramoto N, Toyosaki M, Katayama Y, Koga Y, Murayama S, Sasagawa Y, Shindo M, Teshima T, Hatake K, Maeda Y. Long-term follow-up of belumosudil as second or subsequent line of therapy for steroid-dependent/ resistant cGVHD: clinical outcomes from a Japanese study. Bone Marrow Transplant. 2025 Nov 26. doi: 10.1038/s41409-025-02775-z. Online ahead of print. PMID: 41298855
Goto H, Ito S, Kizaki M, Yamaguchi M, Fukuhara N, Kato K, Saito T, Terui Y, Soshin T, Satomi-Tsushita N, Honda H, Qian C, Izutsu K. Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. Int J Clin Oncol. 2025 Nov;30(11):2352-2361. doi: 10.1007/s10147-025-02865-4. Epub 2025 Sep 2. PMID: 40897939
Okamoto A, Yoshida M, Kasahara S, Ara T, Ozeki K, Morishita T, Ikeda D, Kanaya M, Kajiguchi T, Suzuki Y, Kurahashi S, Horio T, Marumo Y, Oyake T, Saito S, Sawa H, Kimura SI, Nishiyama T, Kondo E, Hiraga J, Hosoi H, Masaki Y, Atsuta Y, Yamamoto H, Miyama T, Goto N, Iriyama C, Mihara K, Inamoto Y, Tomita A. Severe and/or prolonged COVID-19 in hematologic diseases: clinical implications before and during the omicron era. Front Oncol. 2025 Nov 5;15:1687204. doi: 10.3389/fonc.2025.1687204. eCollection 2025. PMID: 41267982
Shah NN, Zinzani PL, Wang M, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss B, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve MA, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada P, Cheah CY. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study. Blood Adv. 2025 Dec 9;9(23):5954-5964. doi: 10.1182/bloodadvances.2024014975. PMID: 40845254
Satake A, Nagate Y, Miyawaki K, Fujiwara Y, Ota S, Muta T, Rai S, Tsurumi H, Suzuki R, Miyake T, Goto H, Fukuhara N, Sakata-Yanagimoto M, Izutsu K, Nishikori M, Shibayama H, Kumode T, Ennishi D, Shimose T, Inubashiri N, Matsumura I, Akashi K, Kato K. Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR). Int J Hematol. 2025 Dec 3. doi: 10.1007/s12185-025-04122-w. Online ahead of print. PMID: 41335368
Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Leão Cordeiro de Farias D, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J. Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. J Clin Oncol. 2025 Dec 20;43(36):3799-3811. doi: 10.1200/JCO-25-01957. Epub 2025 Oct 2. PMID: 41037766
Hamada T, Sugaya M, Sakaida T, Hirai Y, Boki H, Shimauchi T, Hisamoto T, Kiyohara E, Fujii K, Sunagawa K, Ozaki S, Ohnishi K, Izutsu K, Shiratori S, Amagai R, Yonekura K, Iwata M, Miyagaki T, Koga H, Uchi H, Nakamura Y. Japanese Dermatological Association Guidelines: Outlines of Japanese Guidelines for the Management of Primary Cutaneous Lymphomas 2025. J Dermatol. 2025 Dec;52(12):e1017-e1056. doi: 10.1111/1346-8138.70037. Epub 2025 Nov 7. PMID: 41204060
英文総説
Teshima T. Hitting the bullseye in GVHD. Blood. 2025 Apr 10;145(15):1598-1599. doi: 10.1182/blood.2024028109. PMID: 40208654
Hashimoto D. TET3 stirs up trouble via pathogenic Ig class switching. Blood. 2025 Jun 12;145(24):2803-2804. doi: 10.1182/blood.2024028296. PMID: 40504513
Goto H. CRS and ICANS in CAR T-cell therapy for large B-cell lymphoma. J Clin Exp Hematop. 2025;65(4):268-275. doi: 10.3960/jslrt.25072. PMID: 41443883
Teshima T. Is Age No Longer a Barrier to Allogeneic Hematopoietic Stem Cell Transplantation? Transplantation. 2026 Jan 1;110(1):e19-e20. doi: 10.1097/TP.0000000000005459. Epub 2025 Jun 17. PMID: 40524312
英文症例報告
Hara T, Sato A, Soyama A, Matsushima H, Hamada T, Imamura H, Kinoshita A, Migita K, Kawaguchi Y, Adachi T, Hara T, Endo T, Eguchi S. Living Donor Liver Transplantation Using Right Posterior Section Graft in a Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patient With Hemophilia: A Case Report. Transplant Proc. 2025 Jan-Feb;57(1):122-125. doi: 10.1016/j.transproceed.2024.12.033. Epub 2025 Jan 9. PMID: 39794190
Yokoyama E, Hasegawa Y, Wakaki K, Suzuki T, Kajikawa S, Kanaya M, Izumiyama K, Saito M, Morioka M, Nagai J, Ichiki T, Kikuchi R, Okada S, Ohigashi H, Goto H, Onozawa M, Hashimoto D, Mori A, Teshima T, Kondo T. Chronic graft-versus-host disease myelitis successfully treated with rituximab. Int J Hematol. 2025 May;121(5):712-717. doi: 10.1007/s12185-025-03936-y. Epub 2025 Jan 31. PMID: 39888516
Miyachi S, Oshima Y, Yazaki K, Futaki N, Shirai Y, Tanei ZI, Ikebe Y, Iwata I, Ujiie H, Onozawa M, Hirano S, Tanaka S, Yabe I. An Autopsy Case of Amyotrophic Lateral Sclerosis With Sudden Death Showed Histological Features of Lewy Body Disease. Neuropathology. 2025 Aug;45(4):e70009. doi: 10.1111/neup.70009. Epub 2025 Apr 28. PMID: 40295163
Hara T, Enda K, Maeda T, Ikebe Y, Ujiie H, Onozawa M. Asphyxiation due to obstructive fibrinous tracheal pseudomembrane after closure of repeated tracheostomy in a case of von Recklinghausen disease. Respir Med Case Rep. 2025 Sep 26;58:102298. doi: 10.1016/j.rmcr.2025.102298. eCollection 2025. PMID: 41103536
Sato S, Natsuga K, Suto K, Nakagawa M, Endo T, Watanabe M, Ujiie H. Epidermotropic Methotrexate-Associated Diffuse Large B-Cell Lymphoma Presenting With Disseminated Papular Eruptions. J Dermatol. 2025 Dec;52(12):e1061-e1062. doi: 10.1111/1346-8138.17957. Epub 2025 Sep 8. PMID: 40922422
Fujiwara K, Morita S, Hoshino K, Takeda H, Komatsuda K, Kahata K, Nakamaru Y, Homma A. VEXAS syndrome with cochleovestibular involvement. Auris Nasus Larynx. 2025 Dec 18;53(1):70-75. doi: 10.1016/j.anl.2025.12.010. Online ahead of print. PMID: 41418585
〈Invited Speaker〉Optimal GVHD prophylaxis and conditioning regimen for cord blood transplant -The Japanese perspective Takanori Teshima 2025 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Honolulu, USA 2025年2月
〈Invited Speaker〉UCB activity in Japan Takanori Teshima 51st Annual Meeting of the EBMT Florence, Italy 2025年4月
〈Invited Speaker〉HSCT in Japan Takanori Teshima Art of Transplant: Beijing Hematopoietic Stem Cell Transplantation Symposium 2025 Beijing, China 2025年4月
〈Invited Speaker〉Regional transplantation activities in Japan Takanori Teshima The 9th Worldwide Network for Blood and Marrow Transplantation (WBMT) Congress Ulaanbaatar, Mongolia（WEB） 2025年6月
〈Invited Speaker〉Donor selection algorithm in Japan Takanori Teshima The 9th Worldwide Network for Blood and Marrow Transplantation (WBMT) Congress Ulaanbaatar, Mongolia（WEB） 2025年6月
〈Invited Speaker〉Real-world data of CAR-T cell therapy in Japan Takanori Teshima The 8th Vietnamese-French Open Conference on Transfusion-Transplantation-Cell Therapy (VFO- TTCT). The 30th Annual Congress of Asia-Pacific Blood and Marrow Transplantation Group (APBMT). Ho Chi Minh City, Vietnum 2025年9月
〈Keynote Invited Speaker〉Leukemia Immune Microenvironment and GVL Takanori Teshima Taiwan HSCT & Cell Therapy Congress 2025 Changhua, Taiwan 2025年9月
〈Invited Speaker〉Modulation of leukemia immune microenvironment to facilitate GVL Takanori Teshima Cellular Therapy and Immunotherapy Conference 2025 Hangzhou, China 2025年11月
〈Invited Speaker〉Current status of CAR-T cell therapy in Japan Takanori Teshima Cellular Therapy and Immunotherapy Conference 2025 Hangzhou, China 2025年11月
〈ポスター〉Real-world effectiveness in treatment-experienced (TE) people with HIV (PWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) with distinct patterns of self-reported adherence. Boffito M, Brunetta J, Levy I, Yang CJ, Portilla J, Barra E, Vogelmann R, Endo T, Robineau O, Sarmati L, Thorpe D, Marongiu A, Cassidy T, Welzen B. International Conference on HIV/AIDS Taipei city,Taiwan 2025年4月
〈ポスター〉Real-world effectiveness in treatment-experienced (TE) people with HIV (PWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) with distinct patterns of self-reported adherence. Boffito M, Brunetta J, Levy I, Yang CJ, Portilla J, Barra E, Vogelmann R, Endo T, Robineau O, Sarmati L, Thorpe D, Marongiu A, Golar G, Cassidy T, Welzen B. BHIVA Spring Conference 2025 Brighton,UK 2025年4月
〈ポスター〉Real-world effectiveness in treatment-experienced (TE) people with HIV (PWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) with distinct patterns of self-reported adherence. Boffito M, Brunetta J, Levy I, Yang CJ, Portilla J, Barra E, Vogelmann R, Endo T, Robineau O, Sarmati L, Thorpe D, Marongiu A, Cassidy T, Wet J, Welzen B. Canadian Association for HIV Research (CAHR) 2025 Halifax,Canada 2025年5月
〈一般口演〉Ruxolitinib Mitigates GVHD-induced Inflammatory Memory in Intestinal Stem Cells Miyajima T, Hashimoto D, Moriki A, Kojima K, Tsukamoto S, Ichiki T, Saito Y, Li W, Zhang Z, Harada S, Senjo H, Yokoi Y, Hasegawa Y, Ohigashi H, Ara T, Nakamura K, Taniguchi K, Teshima T The 15th JSH International Symposium 2025 in Saga Saga, Japan 2025年5月
〈ポスター〉Real-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan. Fujii F, Onozawa M, Yoshida S, Miyashita N, Kosugi-Kanaya M, Teshima T EHA2025 Congress Milan, Italy 2025年6月
〈特別口演〉HokUS scoring system for predicting the onset and outcome of SOS Souichi Shiratori ICBMT2025 Busan,Korea 2025年9月
〈ポスター〉Prevalence and Risk Factors of Frailty Among Japanese People with HIV: Implications for Health-Related Quality of Life. Nakamura H, Minami R, Narita M, Shirano M, Samukawa S, Endo T, Imamura J, Imahashi M, Wada H, Yamamoto K. 20th European AIDS Conference 2025 Paris,France 2025年10月
〈ポスター〉Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced people with HIV aged >50 years in Asia: pooled 12-month data from observational cohorts. Lee SH, Wang C, Shi L, Ruan L, Endo T, Cermeño JN, Murugesan S, Mo B, Tsai M, Yang CJ. Korean AIDS Society Conferrence Busan,Korea 2025年11月
〈一般口演〉Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) Barba P, Rambaldi A, Boissel N, Doki N, Blaise D, Ciceri F, Briones Meijide J, Kwon M, Fleming S, Blázquez Goñi C, Teshima T, Kato K, Balsat M, Jaeger U, Shune L, Marques Ramos P, Pearson D, Corcoran J, Zia A, Foster M, Masood A, Dickinson M 67th ASH Annual Meeting and Exposition Orlando, USA 2025年12月
〈一般口演〉Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis Mascarenhas J, Scandura J, Gupta V, Shimoda K, McCloskey J, El Chaer F, Bose P, Rampal R, Srisuwananukorn A, Devos T, Mesa R, Passamonti F, Tantravahi S, Ross D, Rein L, Kiladjian J, Teshima T, Yamauchi T, Asada N, Halpern A, Haque T, Paubelle E, Fukuhara N, Vachhani P, Ichii M, Hoffman R, Rotta M, Keng M, Wickenhauser S, Ansaldo K, Seki M, Lee J, Loksa V, Li Z, Foulks J, Kabir S, Shah J, Harrison C 67th ASH Annual Meeting and Exposition Orlando, USA 2025年12月
〈一般口演〉Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update Schuster S, Thieblemont C, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez J, Bachy E, Kato K, Harigae H, Kersten M, Andreadis C, Riedell P, Ho P, Pérez-Simón J, Chen A, Nastoupil L, von Tresckow B, Ferreri A, Teshima T, Patten P, McGuirk J, Offner F, Viardot A, Zinzani P, Zia A, Awasthi R, Ramos R, Ktiouet Dawson M, Hsu P, O'Donovan D, Fowler N, Dreyling M 67th ASH Annual Meeting and Exposition Orlando, USA 2025年12月
〈ポスター〉Serum MMP-7 as an early and specific biomarker for hepatic graft-versus-host disease Hasegawa Y, Hashimoto D, Sugimura S, Moriki A, Kojima K, Tsukamoto S, Ichiki T, Li W, Saito Y, Miyajima T, Zhang Z, Harada S, Kikuchi R, Teshima T 67th ASH Annual Meeting and Exposition Orlando, USA 2025年12月
〈ポスター〉Histone acetyltransferase p300/CBP as a therapeutic target to ameliorate GVHD-induced inflammatory memory Miyajima T, Hashimoto D, Moriki A, Kojima K, Tsukamoto S, Ichiki T, Saito Y, Li W, Zhang Z, Harada S, Senjo H, Yokoi Y, Hasegawa Y, Ohigashi H, Ara T, Nakamura K, Taniguchi K, Teshima T 67th ASH Annual Meeting and Exposition Orlando, USA 2025年12月
〈ポスター〉Thrombotic risk with thrombopoietin receptor agonists in immune thrombocytopenia: Real- world evidence from a multicenter Japanese study. Yoshida M, Iyama S, Horiguchi H, Goto A, Ibata M, Igarashi T, Kondo T, Kakinoki Y, Haseyama Y, Sakai H, Nagashima T, Ota S, Inamura J, Yamamoto S, Wakasa K, Endo T, Yamamoto M, Konuma Y, Takahashi S, Yamauchi N, Fujimoto K, Kobune M. 67th ASH Annual Meeting and Exposition Orlando, USA 2025年12月
〈ポスター〉Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapsed/ refractory FLT3-mutated acute myeloid leukemia: A Japanese nationwide registry study Arai Y, Ohbiki M, Kurata M, Ota S, Tanaka M, Imada K, Fukuda T, Katayama Y, Doki N, Kanda Y, Sakata-Yanagimoto M, Ishida T, Uchida H, Uno S, Teshima T, Takami A, Konuma T, Yanada M, Atsuta Y, Yano S 67th ASH Annual Meeting and Exposition Orlando, USA 2025年12月
〈一般口演〉Goto H, Kumode T, Aizawa K, Fukuhara N, Kato K, Westin JR, Kim W-S, Mori C, Imaizumi T, Maruyama D Efficacy and Safety of Mosunetuzumab (SC) + Polatuzumab Vedotin for Japanese Patients with R/R LBCL 第87回日本血液学会学術集会 神戸 2025年10月
〈一般口演〉Goto H, Okada K, Toyosaki M, Kawakita T, Toubai T, Inagaki Y, Nobuharu F, Kuwazawa H, Ohba A, Fujita M, Hino M, Teshima T Real-World Survey of Pegfilgrastim for PBSC Mobilization and Collection (Final Report) 第87回日本血液学会学術集会 神戸 2025年10月
〈一般口演〉Matsukawa T, Onozawa M, Nagai J, Hidaka D, Yokoyama S, Fujii F, Yoshida S, Kondo T, Senjo H, Ozu S, Takeda Y, Sekiguchi Y, Shimizu T, Takahashi T, Yamamoto S, Teshima T CPX-351 in the real-world data in Hokkaido, Japan:Hokkaido Leukemia Net study 第87回日本血液学会学術集会 神戸 2025年10月
〈一般口演〉Miyajima T, Hashimoto D, Moriki A, Kojima K, Tsukamoto S, Ichiki T, Saito Y, Li W, Zhang Z, Harada S, Senjo H, Yokoi Y, Hasegawa Y, Ohigashi H, Ara T, Nakamura K, Taniguchi K, Teshima T GVHD-induced epigenetic imprinting promotes antigen presentation and apoptosis in IECs 第87回日本血液学会学術集会 神戸 2025年10月
〈一般口演〉Yokoyama K, Chiba M, Takei N, Suto K, Ishio T, Maeda M, Goto H, Endo T, Teshima T, Nakagawa M CRISPR screen identifies the MYLIP–LDLR axis as a regulator of navitoclax sensitivity in PTCL cells 第87回日本血液学会学術集会 神戸 2025年10月
〈一般口演〉Saito Y, Hashimoto D, Moriki A, Kojima K, Tsukamoto S, Ichiki T, Miyajima T, Li W, Zhang Z, Harada S, Senjo H, Hasegawa Y, Ara T, Teshima T Ropeginterferon α-2b enhances GVL effects while ameliorating GVHD 第87回日本血液学会学術集会 神戸 2025年10月
〈一般口演〉Takase K, Miyamoto T, Eto T, Fujisaki T, Tanimoto K, Kikushige Y, Choi I, Imamura Y, Mori A, Nagafuji K, Kawano N, Ohno Y, Takenaka K, Kamimura T, Ogawa R, Ito Y, Teshima T, Yoshimoto G, Ishizuka K, Yonemoto K, Harada M, Akashi K ATRA and ATO combination therapy in newly diagnosed acute promyelocytic leukemia 第87回日本血液学会学術集会 神戸 2025年10月
〈一般口演〉Kanda J, Volt F, Rafii H, Nakasone H, Ruggeri A, Fujii N, Kenzey C, Uchida N, Peffault De La Tour R, Kobayashi H, Scigliuolo G, Kato K, Cappelli B, Ishimaru F, Ichinohe T, Takahashi S, Rocha V, Teshima T, Atsuta Y, Gluckman E Subsequent neoplasms after umbilical cord blood transplantation in Japanese and European populations 第87回日本血液学会学術集会 神戸 2025年10月
〈一般口演〉Makita S, Goto H, Izutsu K, Baba Y, Bar M, Ghodke P, Nishii R, Teshima T Lisocabtagene maraleucel (liso-cel) in Japanese patients with R/R FL: TRANSCEND FL 31-mo follow- up 第87回日本血液学会学術集会 神戸 2025年10月
〈一般口演〉Yuda J, Fukushima K, Shima T, Miyazaki Y, Ikezoe T, Onodera K, Hosono N, Ogawa Y, Teshima T, Asada N, Yamaguchi H, Watts J, Zeidner J, Levis M, Erba H, Papayannidis C, Borate U, Montesinos P, Vives S, Raffoux E, Brunner A, Cai H, Allred C, Xu B, Robson P, Kuwaki T, Hitron M, Shah J, Kantarjian H, Daver N Phase 1/2 study of the Menin-MLL inhibitor enzomenib in Japanese patients with R/R acute leukemia 第87回日本血液学会学術集会 神戸 2025年10月
〈一般口演〉Ichii M, Kikushige Y, Nakamae H, Goto T, Tomita A, Ito S, Teshima T, Kirito K, Ikezoe T, Hatano K, Ueda Y, Tanaka H, Hiramoto N, Osako R, Aoki M, Jinwal R, Takahashi N ASC4FIRST 96-week subgroup analysis: Asciminib in Japanese patients with newly diagnosed CML 第87回日本血液学会学術集会 神戸 2025年10月
〈一般口演〉Murata M, Terakura S, Kanda J, Uchida N, Yoshihara S, Fukuda T, Kataoka K, Ishiwata K, Doki N, Ota S, Sato M, Hino M, Onizuka M, Tabuchi K, Atsuta Y, Teshima T Comparison of mesenchymal stem cells and antithymocyte globulin as second-line acute GVHD therapy 第87回日本血液学会学術集会 神戸 2025年10月
〈ワークショップ〉遠藤知之 もしもの時に慌てないために 〜緊急時編〜 全国ヘモフィリアフォーラム 2025 in 北海道 札幌 2025年10月
〈シンポジウム〉遠藤知之 ビーレジおよびブロック拠点・地域中核病院の診療連携について 全国ヘモフィリアフォーラム 2025 in 北海道 札幌 2025年10月
